Onderzoeksoutput per jaar
Onderzoeksoutput per jaar
Persoonlijk profiel
Expertise gerelateerd aan duurzame ontwikkelingsdoelstellingen van de VN
In 2015 stemden de VN-lidstaten in met 17 wereldwijde duurzame ontwikkelingsdoelstellingen (Sustainable Development Goals, SDG's) om armoede te beëindigen, de planeet te beschermen en voor iedereen welvaart te garanderen. Het werk van deze persoon draagt bij aan de volgende duurzame ontwikkelingsdoelstelling(en):
Vingerafdruk
Verdiep u in de onderzoeksgebieden waarop Henkjan Verkade actief is. Deze onderwerplabels komen uit het werk van deze persoon. Samen vormen ze een unieke vingerafdruk.
- 1 Soortgelijke profielen
Samenwerkingen en hoofdonderzoeksgebieden uit de afgelopen vijf jaar
Recente externe samenwerking op landen-/regioniveau. Duik in de details door op de stippen te klikken of
-
Genome-wide meta-analysis associates donor-recipient non-HLA genetic mismatch with acute cellular rejection post-liver transplantation
TransplantLines Investigators, Nieuwenhuis, L. M., Li, Y., Loza, B.-L., Lambeck, A. J. A., Hu, S., Gacesa, R., Voskuil, M. D., Hepkema, B. G., Jansen, B. H., Blokzijl, H., Verkade, H.-J., van den Heuvel, M. C., Asrani, S., Testa, G., Klintmalm, G., Trotter, J., Olthoff, K. M., Shaked, A. & Keating, B. J. & 3 anderen, , jan.-2025, In: Hepatology communications. 9, 1, 15 blz., e0601.Onderzoeksoutput: Article › Academic › peer review
Open AccessBestand12 Downloads (Pure) -
Molecular adsorbent recirculating system (MARS®) and continuous renal replacement therapy for the treatment of paediatric acute liver failure: two-centre retrospective cohort study
Saxena, R., Alexander, E. C., Bontemps, S., Singla, R., Verkade, H. J., de Meijer, V. E., Kneyber, M. C. J. & Deep, A., mrt.-2025, In: European Journal of Pediatrics. 184, 3, 11 blz., 192.Onderzoeksoutput: Article › Academic › peer review
Open AccessBestand5 Downloads (Pure) -
Obtaining first-line induction in autoimmune hepatitis: Aren't we underestimating prednisolone?
Loeffen, E. A. H., Verkade, H. J. & van Rheenen, P. F., feb.-2025, In: Journal of Hepatology. 82, 2, blz. e78 1 blz.Onderzoeksoutput › Academic › peer review
Open AccessBestand1 Citaat (Scopus)6 Downloads (Pure) -
Sleep duration among breastfed, goat milk-based or cow's milk-based infant formula-fed infants: Post hoc analyses from a double-blind RCT
van Lee, L., Meijer-Krommenhoek, Y., He, T., van der Zee, L. & Verkade, H., mrt.-2025, In: Journal of Pediatric Gastroenterology and Nutrition. 80, 3, blz. 482-489 8 blz.Onderzoeksoutput: Article › Academic › peer review
Open AccessBestand1 Citaat (Scopus)1 Downloads (Pure) -
EASL Clinical Practice Guidelines on genetic cholestatic liver diseases
European Association for the Study of the Liver, aug.-2024, In: Journal of Hepatology. 81, 2, blz. 303-325 23 blz.Onderzoeksoutput: Article › Academic › peer review
Open AccessBestand7 Citaten (Scopus)31 Downloads (Pure)
Activiteiten
-
Medical treatment in sclerosing cholangitis: What works and what doesn’t?
Verkade, H. (Speaker)
6-mei-2022Activiteit: Professional or public presentation › Professional
-
Introduction to the NAPPED Consortium
Verkade, H. (Invited speaker)
29-apr.-2022Activiteit: Professional or public presentation › Professional
-
Improving the prognosis of very rare diseases: what an individual professional or center can do.
Verkade, H. (Invited speaker)
8-dec.-2022Activiteit: Academic presentation › Academic
-
Effects on Serum Bile Acids, Pruritus, and Safety With Up to 72 Weeks of Odevixibat Treatment: Pooled Data From the PEDFIC 1 and PEDFIC 2 Studies in Children With Progressive Familial Intrahepatic Cholestasis
Verkade, H. (Invited speaker)
29-apr.-2022Activiteit: Professional or public presentation › Professional
-
Networking and international registries in rare pediatric lever diseases: the example of the NAPPED registry.
Verkade, H. (Keynote speaker)
1-dec.-2022Activiteit: Academic presentation › Academic
Knipsels
-
Drugs, approval in the EU of 2 new therapies for rare cholestatic diseases
27/09/2024
1 Mediabijdrage
Pers / media: Expert Comment › Popular
-
Ipsen crosses EU finish line with Alagille syndrome drug
24/09/2024
1 Mediabijdrage
Pers / media: Expert Comment › Popular
-
Ipsen’s Kayfanda® Approved in European Union for Rare Liver Disease
24/09/2024
1 Mediabijdrage
Pers / media: Expert Comment › Popular
-
Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease
24/09/2024
1 item van Media-aandacht
Pers / media: Expert Comment › Popular
-
Ipsen today announced that the European Commission has approved Kayfanda® (odevixibat) under exceptional circumstances for the treatment of cholestatic pruritus in Alagille Syndrome (ALGS) in patients aged 6 months or older - Ipsen.com
24/09/2024
1 item van Media-aandacht
Pers / media: Expert Comment › Popular